List of Gene Therapy Companies in Singapore - 6

Biosyngen is a cell therapy company focusing on unmet needs with technology targeting solid tumors and lymphoproliferative diseases. The company’s first-in-class products have entered into Phase I/II clinical trials for nasopharyngeal cancer (ODD and Fast-Track), lymphoproliferative disease and lung cancer. The company continues to enrich its pipeline with further IND submissions. Biosyngen drives its global strategy from the dual HQ in Singapore and Guangzhou. Leverages on the public-private biopharma ecosystem for the better cause. Committed to giving cancer patients a better chance to survive, our pipeline is enriched, covering other major indications which are on track for regulatory registration. Biosyngen seeks breakthrough in collaborations, particularly in translational R&D and clinical development. The company has positioned GMP cell therapy manufacturing facilities in two locations - in Singapore and Guangzhou covering global needs. To quicken drug development from bench-to-bedside, a parallel effort in the form of the Translational Medicine Centre is set up. It is public-private-partnership connecting stakeholders in R&D, Clinical Development, Hospitals, Pharma, Enterprises and Venture Capital.

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s national research and development agency in the public sector. CytoMed is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors.

Juniper Biologics is birthed on the basic premise that access to healthcare is a birthright. We are a science-led healthcare company focused on delivering novel therapies to improve the health and quality of life of patients everywhere by building a growing presence in oncology, rare/orphan diseases and gene therapy. Juniper Biologics was founded on a vision to create a pharmaceutical business that is both agile and innovative. This includes a commitment to providing treatments for unmet needs focused on specialist therapy areas in which we can make the most difference. Our purpose is clear: to do all that we can to change the treatment landscape and address the unmet medical needs of patients, and to do it as quickly as possible. Through bold and transformative science, we’re creating possibilities that have the potential to become the next generation of life-changing medicines. This is just the beginning of our story… and we are just getting started.

Founded in 2016, MegaRobo is a national high-tech enterprise, headquartered in Beijing, with branches in Shenzhen, Shanghai, and Suzhou; the team size is over 300 persons, with R&D personnel accounting for 60%. Focusing on R&D and the application of robot and intelligent Internet of things, MegaRobo has a number of core technologies that are competitive in the world and has applied for over 200 invention patents, which have passed the IOS9001 Quality Management System Certification. Based in China and facing the world, MegaRobo unremittingly provides industry-leading, efficient, and reliable automation solutions for the life sciences, smart retail, and lightweight manufacturing.

Nuevocor is a new biotech start-up in Singapore striving to develop gene therapies for genetic cardiomyopathies. It will leverage a deep understanding of cardiac cell biology, as well as a technology platform encompassing novel gene therapy vectors and proteomics-based target discovery